Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Google Secures Pentagon AI Deal for Classified Projects 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
SAN FRANCISCO, May 03, 2017 -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report first quarter financial results on Tuesday, May 9, 2017, after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).
Audio Webcast
Interested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. A replay of the webcast will be available shortly after the call for a period of two weeks. To access the replay, please dial (888) 843-7419 (domestic) or (630) 652-3042 (international), and use passcode 44595888#.
Dial-In Information
Live (U.S./Canada): (888) 771-4371
Live (International): (847) 585-4405
Confirmation number: 44595888
About FibroGen
FibroGen, Inc., headquartered in San Francisco with subsidiary offices in Beijing and Shanghai, is a leading science-based biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat (FG-4592), the company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase 3 development for anemia in lower risk myelodysplastic syndromes (MDS). Pamrevlumab (FG-3019), a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com.
Contact Karen L. Bergman Vice President, Investor Relations and Corporate Communications FibroGen, Inc. [email protected] (415) 978-1433
